详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Supportive Care Costs Associated with Second-Line Chemotherapy in Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study

文献详情

资源类型：

作者：

机构： [1]Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing, China [2]Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [3]Department of Medical Oncology, Hunan Province Tumor Hospital, Central South University, Changsha, Hunan, China [4]Department of Research and Education, Hunan Province Tumor Hospital, Central South University, Changsha, Hunan, China [5]Department of Respiratory, Xiangya Hospital, Central South University, Changsha, Hunan, China [6]Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai Branch, Shanghai, China [7]Global Health Outcomes Research, Eli Lilly, Indianapolis, IN, USA [8]Division of Social and Administrative Pharmacy, Leslie Dan Faculty of Pharmacy, University of Toronto, 6th floor, 144 College Street, Toronto, ON M5S 3M2, Canada [9]Division of Health Outcome Research, Normin Health China Office, Changsha, Hunan, China [10]Normin Health, Toronto, ON, Canada

出处：

DOI：

ISSN：

摘要：

Purpose: To compare supportive care costs associated with second-line chemotherapy for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) in Chinese patients. Methods: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for advNS-NSCLC in four Chinese hospitals from 2007 to 2012. The best matched pairs between pemetrexed and other regimens were identified using propensity score methods for head-to-head comparisons of supportive care costs per treatment cycle. Linear regression analyses were performed to rank log10 scale of supportive care costs per treatment cycle associated with chemotherapy by tumor response and hematologic toxicity. Results: 384 patients were included to create propensity score-matched treatment groups for pemetrexed singlet versus docetaxel singlet, platinum/pemetrexed, and platinum/docetaxel, respectively. Pemetrexed singlet was associated with significantly less supportive care costs per treatment cycle than the two doublets (platinum/pemetrexed: median difference −RMB 9,877, p = 0.003; platinum/docetaxel: median difference −RMB 8,370, p = 0.009; 1 RMB = 0.16 USD) but not docetaxel singlet in matched patients. Of the four studied chemotherapy regimens, pemetrexed singlet was associated with the lowest log10 scale of supportive care costs per treatment cycle in patients with tumor control (coefficient relative to docetaxel singlet −1.049, p < 0.001) or leukopenia (coefficient relative to docetaxel singlet −0.991, p = 0.034). Conclusion: Pemetrexed singlet cost significantly less for supportive care than pemetrexed or docetaxel-based doublets when treating Chinese patients with AdvNS-NSCLC in the second-line setting. Pemetrexed singlet was also associated with significantly less supportive care costs per treatment cycle than docetaxel singlet in patients with tumor control or leukopenia. © 2015, The Author(s).

基金：

语种：

PubmedID：

第一作者：

第一作者机构： [1]Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing, China

通讯作者：

通讯机构： [8]Division of Social and Administrative Pharmacy, Leslie Dan Faculty of Pharmacy, University of Toronto, 6th floor, 144 College Street, Toronto, ON M5S 3M2, Canada [10]Normin Health, Toronto, ON, Canada

推荐引用方式(GB/T 7714)：

APA：

MLA：